I watched on the HC screen so May not have been counted either (wasn’t redirected)… was a good preso - they are full on now in clinical development of two potentially break through assets and the autologous platform may also create some excellent value - mix of a cure (full response and no remission) and a disease stability. I think the 0201 platform will need a bit more science but for an autologous platform to have one full response is impressive at this stage so they know functionally it’s safe as well - safety is a huge positive so far if they can get some food efficacy wirh CHM 1101 that could be fast tracked to help patients. Am bullish but the funding is the one downer - too slow or fast(?) to raise (the market is now turning a bit better for biotech) and opaque messaging on sources (and loss of sources).
CHM Price at posting:
4.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)